PUBLISHER: The Business Research Company | PRODUCT CODE: 1945350
PUBLISHER: The Business Research Company | PRODUCT CODE: 1945350
Implantable drug delivery devices are specialized drug delivery systems that are surgically implanted beneath the skin. These devices release drugs from a reservoir directly into the bloodstream, enabling targeted drug delivery and reducing the need for larger doses, which, in turn, minimizes potential side effects.
The primary product categories within the domain of implantable drug delivery devices include contraceptive implants, spinal implants, brachytherapy seeds, drug-eluting stents, bioabsorbable stents, intraocular stents, infusion pumps, and various other devices. Spinal implants, for instance, aid surgeons in treating deformities, providing spinal stability, and promoting fusion during surgical procedures. These devices employ a range of technologies, including diffusion, osmosis, magnetic mechanisms, and others. They find applications in a variety of medical fields, such as contraception, ophthalmology, cardiovascular treatments, diabetes management, oncology, the treatment of autoimmune diseases, and other medical areas.
Tariffs are influencing the implantable drug delivery devices market by increasing costs of imported polymers, micro-pumps, electronic components, and precision manufacturing equipment used in implant fabrication. North America and Europe are most affected due to reliance on specialized imported materials, while Asia-Pacific faces higher production costs for export-oriented implants. These tariffs are elevating device prices and extending development timelines. At the same time, they are encouraging local manufacturing, regional material sourcing, and innovation in cost-efficient implantable drug delivery platforms.
The implantable drug delivery devices market research report is one of a series of new reports from The Business Research Company that provides implantable drug delivery devices market statistics, including implantable drug delivery devices industry global market size, regional shares, competitors with a implantable drug delivery devices market share, detailed implantable drug delivery devices market segments, market trends and opportunities, and any further data you may need to thrive in the implantable drug delivery devices industry. This implantable drug delivery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The implantable drug delivery devices market size has grown strongly in recent years. It will grow from $21.94 billion in 2025 to $23.91 billion in 2026 at a compound annual growth rate (CAGR) of 9.0%. The growth in the historic period can be attributed to advancements in implantable medical device design, rising prevalence of chronic diseases, increased use of long-term drug therapies, growth in minimally invasive surgical procedures, expansion of oncology and cardiovascular treatments.
The implantable drug delivery devices market size is expected to see strong growth in the next few years. It will grow to $33.39 billion in 2030 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to increasing development of smart implantable devices, rising demand for personalized drug delivery, expansion of biodegradable implant technologies, growing investments in combination drug-device products, increasing regulatory approvals for implantable therapies. Major trends in the forecast period include increasing adoption of controlled-release implant systems, rising use of bio-absorbable implant materials, growing demand for site-specific drug delivery, expansion of miniaturized implantable devices, enhanced focus on patient compliance.
The increasing incidence of chronic diseases is expected to drive the growth of the implantable drug delivery devices market in the coming years. Chronic diseases are long-lasting medical conditions that persist for extended periods, typically three months or more. The rise in chronic diseases is largely attributed to widespread unhealthy lifestyle habits, such as poor nutrition, physical inactivity, and tobacco use, which significantly increase the risk of non-communicable diseases globally. Implantable drug delivery devices are increasingly being used to provide long-term, controlled medication administration for chronic conditions, improving patient compliance and treatment effectiveness. For example, in August 2025, the Centers for Disease Control and Prevention, a US-based public health agency, reported that 90% of the nation's $4.9 trillion in annual healthcare spending is attributed to individuals with chronic and mental health conditions. Furthermore, more than 84,000 Americans die each year from heart disease or stroke, with the costs associated with cardiovascular diseases projected to reach approximately $2 trillion by 2050. As a result, the growing incidence of chronic diseases is driving the demand for implantable drug delivery devices.
The increasing healthcare expenditure is expected to drive the growth of the implantable drug delivery devices market in the future. Healthcare expenditure refers to the total amount of money spent on healthcare services, products, and public health activities within a country or system, covering areas such as hospital care, physician services, medicines, medical devices, long-term care, and preventive programs. As the burden of chronic diseases rises, there is an increasing need for continuous treatment, long-term medication, and frequent clinical visits, which significantly raises overall healthcare spending. The growing healthcare expenditure supports the implantable drug delivery devices market by facilitating the wider adoption of advanced, long-term treatment technologies. For example, in April 2025, the Office for National Statistics, a UK-based government department, reported that between 2023 and 2024, overall healthcare spending increased by 6.5% in nominal terms and by 2.4% in real terms after adjusting for inflation. As a result, the growing healthcare expenditure is contributing to the expansion of the implantable drug delivery devices market.
In May 2024, Arecor, a UK-based biopharmaceutical company specializing in novel formulations, partnered with Medtronic to develop a highly concentrated yet stable liquid formulation of an undisclosed Medtronic therapeutic product. As part of this collaboration, Medtronic will fund the formulation and development of an Arestat-enabled insulin, specifically designed for implantable delivery. This partnership aims to enhance therapeutic precision and improve patient outcomes. Medtronic, a US-based health technology company, is focused on developing a high-concentration, thermostable insulin for use in next-generation implantable pumps.
Major companies operating in the implantable drug delivery devices market are AbbVie Inc., Bayer HealthCare, Medtronic Inc., Nucletron, Boston Scientific Corporation, Abbott Laboratories, Bausch and Lomb Inc., Merck & Co. Inc., Genentech Inc, EyePoint Pharmaceuticals Inc., DSM Biomedical, Delpor Inc., Teleflex Incorporated, Biotronik Inc., Alcon Inc., Terumo Corporation, Endologix Inc., Innocoll Biotherapeutics, Atossa Therapeutics Inc., Intersect ENT, Microchips Biotech, Theradaptive Inc., CollPlant, Intarcia Therapeutics, Glaukos Corporation
North America was the largest region in the implantable drug delivery devices market in 2025. Asia-Pacific was the second-largest region in the implantable drug delivery devices market report. The regions covered in the implantable drug delivery devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the implantable drug delivery devices market report are China, India, Japan, Australia, Indonesia, South Korea, Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, Taiwan, New Zealand, UK, Germany, France, Italy, Spain, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Russia, Czech Republic, Poland, Romania, Ukraine, USA, Canada, Mexico, Brazil, Chile, Argentina, Colombia, Peru, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
The implantable drug delivery devices market consists of sales of contraceptive implants, spinal implants, brachytherapy seeds, drug-eluting stents, bio-absorbable stents, intraocular stents, infusion pumps, and others. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Implantable Drug Delivery Devices Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses implantable drug delivery devices market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for implantable drug delivery devices ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The implantable drug delivery devices market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.